| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY)
ALNY Technical Analysis
4
| As on 9th Jun 2023 ALNY SHARE Price closed @ 190.83 and we RECOMMEND Buy for LONG-TERM with Stoploss of 169.29 & Strong Buy for SHORT-TERM with Stoploss of 155.28 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ALNYSHARE Price
| Open | 190.65 | Change | Price | % |
| High | 192.93 | 1 Day | 0.40 | 0.21 |
| Low | 189.67 | 1 Week | 2.57 | 1.37 |
| Close | 190.83 | 1 Month | -11.32 | -5.60 |
| Volume | 457600 | 1 Year | -3.74 | -1.92 |
| 52 Week High 241.31 | 52 Week Low 120.42 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ALNY Daily Charts |
ALNY Intraday Charts |
Whats New @ Bazaartrend |
ALNY Free Analysis |
|
|
ALNY Important Levels Intraday
| RESISTANCE | 197.11 |
| RESISTANCE | 195.10 |
| RESISTANCE | 193.85 |
| RESISTANCE | 192.61 |
| SUPPORT | 189.05 |
| SUPPORT | 187.81 |
| SUPPORT | 186.56 |
| SUPPORT | 184.55 |
ALNY Forecast April 2024
| 4th UP Forecast | 264.6 |
| 3rd UP Forecast | 240.94 |
| 2nd UP Forecast | 226.32 |
| 1st UP Forecast | 211.69 |
| 1st DOWN Forecast | 169.97 |
| 2nd DOWN Forecast | 155.34 |
| 3rd DOWN Forecast | 140.72 |
| 4th DOWN Forecast | 117.06 |
ALNY Weekly Forecast
| 4th UP Forecast | 262.50 |
| 3rd UP Forecast | 239.51 |
| 2nd UP Forecast | 225.31 |
| 1st UP Forecast | 211.10 |
| 1st DOWN Forecast | 170.56 |
| 2nd DOWN Forecast | 156.35 |
| 3rd DOWN Forecast | 142.15 |
| 4th DOWN Forecast | 119.16 |
ALNY Forecast2024
| 4th UP Forecast | 432.46 |
| 3rd UP Forecast | 354.97 |
| 2nd UP Forecast | 307.07 |
| 1st UP Forecast | 259.17 |
| 1st DOWN Forecast | 122.49 |
| 2nd DOWN Forecast | 74.59 |
| 3rd DOWN Forecast | 26.69 |
| 4th DOWN Forecast | -50.8 |
Alnylam Pharmaceuticals Inc ( NASDAQ USA Symbol : ALNY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ALNY Business Profile
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Address: 675 West Kendall Street, Cambridge, MA, United States, 02142
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service